No inhibitors were detected and no cases of anaphylaxis were reported in any patients. Three treatment-related adverse events were reported in 2 of the 73 (2.7%) patients, all of which were mild and transient: dysgeusia (distortion of the sense of taste) occurred twice in one patient and pain in extremity occurred once in another patient. More than 70 percent of subjects (56 of 73) had 50 or more exposure days to BAX 326 during the study.''As a company committed to advancing care for people with hemophilia for more than 60 years, Baxter continues to deliver significant innovation in the field of hemophilia. If it is approved, BAX 326 will expand treatment options for patients,'' said Prof. Harmut J. Ehrlich, M.D., vice president of global research and development in Baxter’s BioScience business.
Baxter Presents Phase I/III Data Evaluating Safety And Efficacy Of BAX 326, An Investigational Recombinant Factor IX For Hemophilia B, Showing More Than 40 Percent Of Patients Experienced No Bleeds
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts